Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Bristol-Myers Squibb
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, and Roche/Genentech are among those companies announcing clinical oncology achievements ahead of ...
    5-16-2013
  • Biotechs Need to Walk the Walk on Drug Value
    ... Two months later, 10 pharma giants-AbbVie, AstraZeneca (AZ), Boehringer Ingelheim, Bristol-Myers Squibb (BMS), GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer, Roche, and ...
    5-15-2013
  • Lilly Halts Development of Lymphoma Drug After Phase III Failure
    ... Lilly said in January it lost Bristol-Myers Squibb as a partner in developing necitumumab for North America and Japan. Enzastaurin is an oral small molecule that works by acting as ...
    5-10-2013
  • Companion Diagnostics: 52 Pick-Up
    ... CDx Under Development (continued) Life Technologies (being acquired by Thermo Fisher Scientific) and Bristol-Myers Squibb Agreement announced September 17, 2012 Master Development ...
    5-9-2013
  • BMS Partners Again with Ambrx, in Up-to-$112M-and-Up ADC Collaboration
    Bristol-Myers Squibb (BMS) will use Ambrx's protein medicinal technology to develop antibody drug conjugates (ADCs) for unspecified cancer indications, in an up-to-$112 ...
    5-3-2013
  • OBT Joins Boehringer Ingelheim in Cancer Drug Collaboration
    with Seattle Genetics, Medarex (since acquired by Bristol-Myers Squibb), Amgen, Biosite (now Alere), and BioWa, as well as development alliances with Sanofi and Menarini. ...
    4-29-2013
  • Merck Joins Pfizer to Develop Type 2 Diabetes Drug
    However, not all SGLT2 drugs have overcome regulatory scrutiny. Bristol-Myers Squibb and AstraZeneca won approval in November 2012 from the European Commission for Forxiga, but FDA ...
    4-29-2013
  • GEN | Biolinks
    ... Ingelheim Boehringer Ingelheim Brandeis University Brigham Young University Bristol-Myers Squibb British In Vitro Diagnostics Association (BIVDA) Bruker Daltonics Business Oregon ...
  • E&Y: Biotechs Must Walk the Walk on Drug Value
    Two months later, 10 pharma giants-AbbVie, AstraZeneca (AZ), Boehringer Ingelheim, Bristol-Myers Squibb (BMS), GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer, Roche, and ...
    4-22-2013
  • BMS, Santaris Make Potentially $100M+ mRNA-Targeting Deal
    Bristol-Myers Squibb is teaming up with Santaris Pharma to discover and develop novel medicines using Santaris Pharma's locked nucleic acid (LNA) drug platform. Santaris Pharma is ...
    4-16-2013
  • People in the News
    Before that, he held sales and product management positions at Westwood-Squibb/Bristol Myers-Squibb. Kymab appointed Duncan Casson, M.D. , as chief development officer and Ken ...
    4-15-2013
  • CEO Perks
    Lamberto Andreotti Bristol-Myers Squibb CEO Perks and "all other" compensation: $818,078, all of it consisting of company contribution to savings plans. In its Proxy Statement for ...
    4-12-2013
  • BMS Grows Biologics in $250M Expansion
    Bristol-Myers Squibb today unveiled plans for a $250 million expansion of its large-scale biologics manufacturing facility in Devens, MA, that will introduce capabilities in ...
    4-11-2013
  • BMS Shores Up R&D after Trial Failure, Plavix Patent Loss
    Bristol-Myers Squibb yesterday named Francis Cuss as executive vp and chief scientific officer effective July 1, as the pharma giant moved to shore up an R&D effort set back by the ...
    4-8-2013
  • Astellas, Ambrx Launch Up-To-$300M ADC Partnership
    Astellas and Merck have joined Bristol-Myers Squibb, Eli Lilly, and several undisclosed companies that have launched collaborations with Ambrx to use its technology in developing ...
    4-5-2013

  • Journal Articles

  • Hypolipidemic and Antioxidant Potentials of Xylopia aethiopica...
    Sarah O. Nwozo, Bosede F. Orojobi, Oluwatosin A. Adaramoye
    Journal of Medicinal Food
    .../kg/0.3?mL, plant extracts at 250?mg/kg, and cholestyramine (Questran®, Bristol-Myers Squibb, Hounslow, United Kingdom) at 0.26?g/kg five times a week for 8 consecutive weeks. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll